It was great to be at BIO in San Francisco this year and see so many of our friends. If you didn't have a chance to take home our poster showing the partnering deals done by the top global pharma companies with biotech companies, grouped by therapeutic area, you can get one here.
The Official Data Room for BIO
ShareVault is proud to have been selected as the official data room provider for BIO and more than 30 other life sciences industry associations. We were selected because ShareVault is the only data room that provides features specifically developed to accelerate BioPharma partnering due diligence.
Much Faster Review of Regulatory Documents
Our exclusive document-to-document hyperlinking allows faster review of regulatory documents in your IND, NDA and subsequent resubmissions.
Fastest Data Room
ShareVault is a responsive, low-latency web application, making it the fastest data room on the market. ShareVault is quick to configure and set up, with fast drag-and-drop uploading, easy-to-organize tagging and batch operations that make it a snap to manage users and configure permissioning. It’s also faster for your end users, with high speed scrolling, instant fulltext search and a plug-in free document viewer that works in any browser.
Used by 44 of the 45 Top Global Pharma Companies
Big Pharma is already familiar with using ShareVault for BioPharma due diligence, which means that you can rest assured that your due diligence process will be streamlined – a good data room should speed up due diligence, not get in the way.
Free Resources for BioPharma Dealmakers
Did you know that ShareVault, in addition to being the best data room provider to the BioPharma industry, has free resources for BioPharma dealmakers? Here are just a few of our white papers targeted to BioPharma partnering:
Must-Know Finance Concepts for Life Sciences Valuations
This white paper, based on the webinar by the same name, presents an introduction to the key concepts and most common methodologies used to evaluate life sciences assets.
If you are an entrepreneur who is, or will be, raising financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the investing sector, you'll benefit from this overview of the key concepts used in life sciences valuation discussions.
Authors: Jeff Karan and John Selig, Mavericks Capital
What's Hot & What's Not in Immuno-Oncology Licensing
If you are developing an immuno-oncology drug or working toward in- or out-licensing of an immuno-oncology drug, you will want to read these perspectives.
- Linda Pullan, PhD | Pullan Consulting
- Jeff Bockman, PhD | Defined Health
- Ferran Prat, PhD | MD Anderson
- Axel Hoos, MD, PhD | GlaxoSmithKline Pharmaceuticals (GSK)
- Nate Sanburn, MS | Eli Lilly & Company (Lilly)
Four Essential Steps to Successful BioPharma Partnering
Successful BioPharma partnerships don't happen by accident. And negotiating an out-licensing deal can be a daunting task – especially since the company may also be progressing the clinical portfolio.
This white paper, based on the webinar by the same name, provides you perspectives on the major steps required for a successful transaction.
Gautam Aggarwal, a partner with Triangle Insights Group, walks you through the essential steps that will maximize your chance of partnering success.
Successful Biotech Licensing Negotiations
Biotech companies seeking to partner their drug candidates should decide in advance what they want to achieve in deal negotiations. Getting the best outcome depends on non-financial, as well as financial terms. In this white paper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.
Linda M. Pullan, Ph.D. | Pullan Consulting